Cybin has dosed the last patient in Part B of its three-part CYB004-E Phase I clinical trial of CYB004 in healthy volunteers.

CYB004 is being evaluated as a potential therapy for the treatment of generalised anxiety disorder with or without major depressive disorder.

The study is evaluating the pharmacokinetics, pharmacodynamics, and safety of escalating doses of intravenous N,N-dimethyltryptamine (IV DMT) molecule CYB004 in healthy subjects.

Being conducted at the Centre for Human Drug Research in the Netherlands, the CYB004-E study is said to be one of the largest Phase I DMT trials till date.

Cybin CEO Doug Drysdale said: “We are pleased with the continued progress we are making with our CYB004 programme and excited to reach our next key milestone of first-in-human dosing with our novel CYB004 molecule.

“Through Part C of the trial, we will have the ability to evaluate CYB004 in humans earlier than expected and potentially demonstrate the advantages of deuteration on pharmacokinetic/pharmacodynamic parameters, enabling a less invasive and more convenient dose form that may eliminate the need for specialised and costly clinical centres for dosing.”

Part C of the study intends to evaluate IV bolus along with infusion regimens of CYB004 in a crossover manner.

For further clinical trials, dose selection and formulation will be decided based on the results of Part B and C studies.

Topline data from the completed Phase I study is expected in the third quarter of this year.